Filtered By:
Source: Heart Rhythm
Drug: Warfarin
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 21 results found since Jan 2013.
Stroke prevention in atrial fibrillation—An Asian stroke perspective
Despite relatively lower prevalence of atrial fibrillation (AF) in Asians (~1%) than in Caucasians (~2%), Asia has a much higher overall disease burden because of its proportionally larger aged population. For example, on the basis of reported age-adjusted prevalence rates and projected population figures in China, there will be an estimated 5.2 million men and 3.1 million women with AF older than 60 years by year 2050. Stroke is a disabling complication of AF that is of increasing cause for concern in Asians patients. Implementing consensus expert recommendations for managing stroke risk in patients with AF can considerab...
Source: Heart Rhythm - March 18, 2013 Category: Cardiology Authors: Hung-Fat Tse, Yong- Jun Wang, Moheeb Ahmed Ai-Abdullah, Annette B. Pizarro-Borromeo, Chern-En Chiang, Rungroj Krittayaphong, Balbir Singh, Amit Vora, Chun-Xue Wang, Mohammad Zubaid, Andreas Clemens, Paul Lim, Dayi Hu Tags: Contemporary Review--Associate Editor: Sami Viskin Source Type: research
Po-713-05 ischemic stroke after prophylaxis with left atrial appendage closure vs non-warfarin oral anticoagulants: a “real-world” multicenter comparison of stroke severity
In randomized trials, strokes occurring in patients who have received left atrial appendage closure (LAAC) devices have been less severe than in patients receiving warfarin prophylaxis - an observation thought related to warfarin ’s higher rate of hemorrhagic stroke (which are known to have worse outcomes). Similar stroke rates have been described with LAAC vs NOACs (non-warfarin oral anticoagulants), but the low hemorrhagic stroke rate of NOACs raises the question of stroke severity between these two therapies.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Mohit K. Turagam, Iwanari Kawamura, Domenico G. Della Rocca, Pavel Hala, Thomas Flautt, Deji Adedokun, Moritoshi Funasako, Daniel Ross Musikantow, Srinivas R. Dukkipati, David H. Yoo, Petr Neuzil, Devi G. Nair, Douglas N. Gibson, Miguel Valderrabano, Andr Source Type: research
Warfarin Use and the Risk of Mortality, Stroke, and Bleeding in Hemodialysis Patients with Atrial Fibrillation
The optimal management of stroke prophylaxis in hemodialysis patients with atrial fibrillation is controversial.
Source: Heart Rhythm - February 5, 2017 Category: Cardiology Authors: Brandon Kai, Yuliya Bogorad, Leigh-Ann N. Nguyen, Su-Jau Yang, Wansu Chen, Hillard T. Spencer, Albert Y.-J. Shen, Ming-Sum Lee Source Type: research
Benefits of non –vitamin K antagonist oral anticoagulants in patients with atrial fibrillation go beyond stroke prevention
The last decade has produced a large body of robust randomized controlled trial (RCT) data investigating the use of non –vitamin K antagonist oral anticoagulants (NOACs) in nonvalvular atrial fibrillation (AF).1–4 Compared with warfarin, dabigatran and apixaban have been found to reduce the combined outcome of stroke and systemic embolism. In addition, apixaban and edoxaban significantly reduce major bleeding. Fu rthermore, a pooled meta-analysis has demonstrated superior efficacy and overall safety of the NOACs.
Source: Heart Rhythm - January 15, 2017 Category: Cardiology Authors: Jay A. Montgomery, Gregory F. Michaud Tags: Editorial Commentary Source Type: research
A New Model to Predict Ischemic Stroke in Patients with Atrial Fibrillation Using Warfarin or Direct Oral Anticoagulants
Stroke risk stratification scores (e.g., CHA2DS2-VASc) are used to tailor therapeutic recommendations for patients with atrial fibrillation (AF) in different risk groups.
Source: Heart Rhythm - December 11, 2018 Category: Cardiology Authors: J ’Neka S. Claxton, Richard F. MacLehose, Pamela L. Lutsey, Faye L. Norby, Lin Y. Chen, Wesley T. O’Neal, Alanna M. Chamberlain, Lindsay G.S Bengtson, Alvaro Alonso Source Type: research
Left atrial appendage closure: A new technique for clinical practice
Conclusion: This review concludes that it is now appropriate to consider these techniques for patients with AF who are at high risk for stroke for whom effective conventional or novel anticoagulant therapy is not available or who present problems in managing drug treatment.
Source: Heart Rhythm - December 2, 2013 Category: Cardiology Authors: A John Camm, Antonio Colombo, Giorgio Corbucci, Luigi Padeletti Tags: Contemporary Review--Section Editor: Sami Viskin Source Type: research
Editorial Commentary: Anticoagulation for atrial fibrillation in dialysis patients: What is known and what does the future hold?
The association between atrial fibrillation and stroke is well established and, in the general population, anticoagulation with warfarin can reduce the incidence of stroke by 60% with an acceptable bleeding risk.1, 2 Patients who are on hemodialysis have an increased prevalence of atrial fibrillation possibly secondary to comorbid conditions and hemodialysis itself causing dramatic swings in fluid and electrolytes and affecting cardiac dimensions.3 There are also substantially higher rates of ischemic stroke in this population attributable both to frequently co-occurring traditional stroke risk factors as well as the incre...
Source: Heart Rhythm - February 18, 2017 Category: Cardiology Authors: Timothy M. Markman, Saman Nazarian Source Type: research
Anticoagulation for atrial fibrillation in dialysis patients: What is known and what does the future hold?
The association between atrial fibrillation and stroke is well established, and in the general population, anticoagulation with warfarin can reduce the incidence of stroke by 60% with an acceptable bleeding risk.1,2 Patients who are on hemodialysis have an increased prevalence of atrial fibrillation, possibly secondary to comorbid conditions and hemodialysis itself causing dramatic swings in fluid and electrolytes and affecting cardiac dimensions.3 There are also substantially higher rates of ischemic stroke in this population attributable both to frequently co-occurring traditional stroke risk factors and to the increased...
Source: Heart Rhythm - February 18, 2017 Category: Cardiology Authors: Timothy M. Markman, Saman Nazarian Tags: Editorial Commentary Source Type: research
The who, how, and why of screening patients for atrial fibrillation: More questions than answers
An estimated 100,000 –125,000 of the 610,000 strokes per year in the United States are associated with atrial fibrillation (AF).1 AF-related strokes cause larger cortical loss, disability, cost, and mortality compared with strokes not related to AF. In a pooled trial analysis, oral anticoagulation with warfarin lowere d AF stroke incidence by 64%.2 However, many AF patients have minimal to no symptoms and remain undiagnosed until complications occur. Given the devastating consequences of stroke and the high prevalence of AF, the value of screening to detect asymptomatic AF for the purpose of initiating anticoagul ation p...
Source: Heart Rhythm - June 17, 2017 Category: Cardiology Authors: Anne B. Curtis, Alexander Hattoum Tags: Editorial Commentary Source Type: research
Percutaneous Left Atrial Appendage Closure is Not Ready for Routine Clinical Use
Both Watchman and NOACs are treatment strategies designed to prevent stroke in patients with atrial fibrillation (AF). For practical reasons device trials cannot enroll as many patients as drug trials, however, a comparison of the Watchman and NOAC trials serves to highlight the challenge of predicting efficacy of a treatment when event rates are low. Four large noninferiority trials compared NOAC to warfarin therapy for stroke prevention in patients with AF. 1-4 We will focus on the RELY and ARISTOTLE trials because they enrolled patients with similar stroke-risk (age, CHADS2 score, etc.) to those in the Watchman trials.
Source: Heart Rhythm - October 10, 2017 Category: Cardiology Authors: John Mandrola, Andrew Foy, Gerald Naccarelli Source Type: research
Left Atrial Appendage Closure Devices: A Reasonable Therapeutic Alternative
Preventing stroke is arguably the most important goal in the management of atrial fibrillation (AF). For decades, oral anticoagulation (OAC) has been the therapeutic mainstay for stroke prophylaxis – initially warfarin, and more recently, non-warfarin oral anticoagulants (NOACs). However, many patients are poor candidates for lifelong OAC therapy. This clinical need prompted the emergence of the therapeutic alternative, left atrial appendage closure (LAAC). Herein, I discuss the clinical evi dence supporting LAAC’s role as a reasonable stroke prevention alternative.
Source: Heart Rhythm - October 10, 2017 Category: Cardiology Authors: Vivek Y. Reddy Source Type: research
EP News: Allied Professionals
Using data from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, Lopes et al (J Am Coll Cardiol 2018;71:1063, PMID 29519345) sought to determine the effect of digoxin on mortality in patients with atrial fibrillation (AF). ARISTOTLE is a pivotal trial involving ∼18,000 patients with AF and at least 1 risk factor for stroke with randomization to apixaban or warfarin. T he present study is a post hoc analysis of those patients who were on digoxin at baseline as compared with those not on digoxin as well as an analysis of patients taking digoxin during the cour...
Source: Heart Rhythm - April 27, 2018 Category: Cardiology Authors: Erica S. Zado Source Type: research
Stroke Prevention Using Dabigatran in the Very Elderly with Atrial Fibrillation
Little is known about the clinical benefit of a non-vitamin K antagonist oral anticoagulant (NOAC) compared with warfarin in elderly Chinese patients with atrial fibrillation (AF).
Source: Heart Rhythm - September 18, 2015 Category: Cardiology Authors: Pak-Hei CHAN, Duo HUANG, Jojo HAI, Wen-Hua LI, Li-Xue YIN, Esther W. CHAN, Ian C.K. WONG, Chu-Pak LAU, Chern-En Chiang, Jun ZHU, Hung-Fat TSE, Chung-Wah SIU Source Type: research
Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation
Little is known about the clinical benefit of a non–vitamin K antagonist oral anticoagulant compared with warfarin in elderly Chinese patients with atrial fibrillation (AF).
Source: Heart Rhythm - September 18, 2015 Category: Cardiology Authors: Pak-Hei Chan, Duo Huang, Jojo Hai, Wen-Hua Li, Li-Xue Yin, Esther W. Chan, Ian C.K. Wong, Chu-Pak Lau, Chern-En Chiang, Jun Zhu, Hung-Fat Tse, Chung-Wah Siu Source Type: research
Percutaneous left atrial appendage closure improves left atrial mechanical function through Frank –Starling mechanism
Modifications in left atrial (LA) flow velocities after left atrial appendage (LAA) exclusion have been shown in animal and ex vivo models. In a substudy of PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation), an objective improvement in quality of life was observed after LAA closure.
Source: Heart Rhythm - February 6, 2017 Category: Cardiology Authors: Augustin Coisne, Rosario Pilato, Fran çois Brigadeau, Didier Klug, Christelle Marquie, Zouheir Souissi, Marjorie Richardson, Stéphanie Mouton, Anne-Sophie Polge, Patrizio Lancellotti, Dominique Lacroix, David Montaigne Source Type: research
